KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Cash from Investing Activities readings, the most recent being $229.0 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 13.93% to $229.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $765.0 million, a 9.89% decrease, with the full-year FY2025 number at $737.0 million, down 6.94% from a year prior.
  • Cash from Investing Activities hit $229.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from $165.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $302.0 million in Q2 2023 to a low of $135.0 million in Q3 2025.
  • Median Cash from Investing Activities over the past 5 years was $181.0 million (2023), compared with a mean of $198.9 million.
  • Biggest five-year swings in Cash from Investing Activities: crashed 68.31% in 2022 and later surged 79.17% in 2023.
  • Teva Pharmaceutical Industries' Cash from Investing Activities stood at $168.0 million in 2022, then surged by 79.17% to $301.0 million in 2023, then crashed by 32.89% to $202.0 million in 2024, then dropped by 18.32% to $165.0 million in 2025, then surged by 38.79% to $229.0 million in 2026.
  • The last three reported values for Cash from Investing Activities were $229.0 million (Q1 2026), $165.0 million (Q4 2025), and $135.0 million (Q3 2025) per Business Quant data.